Tuesday, October 13, 2026

Carnival Stock Went Down By Over 18% In The Last 5 Sessions

Carnival Stock Went Down By Over 18% In The Last 5 Sessions

(VIANEWS) - Shares of Carnival (NYSE: CCL) dropped by a staggering 18.9% in 5 sessions from $10.53 to $8.54 at 12:37 EST on Wednesday, after five successive sessions in a row of losses. NYSE is sliding 2.57% to $14,561.30, following the last session's upward trend.

Carnival's last close was $9.07, 57.81% below its 52-week high of $21.50.

About Carnival

Carnival Corporation & plc engages in the provision of leisure travel services. The company operates a fleet of more than 90 ships visit approximately 700 ports under AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, Princess Cruises, P&O Cruises (Australia), P&O Cruises (UK), and Seabourn brand names. It also provides port destinations and other services, as well as owns and owns and operates hotels, lodges, glass-domed railcars, and motorcoaches. The company sells its cruises primarily through travel agents, tour operators, vacation planners, and websites. It operates in the United States, Canada, Continental Europe, the United Kingdom, Australia, New Zealand, Asia, and internationally. Carnival Corporation & plc was founded in 1972 and is headquartered in Miami, Florida.

Earnings Per Share

As for profitability, Carnival has a trailing twelve months EPS of $-13.02.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -63.44%.

Volume

Today's last reported volume for Carnival is 24588729 which is 39.75% below its average volume of 38922700.

More news about Carnival (CCL).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com